{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T21:36:26Z","timestamp":1793223386745,"version":"4.5.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Fluoroquinolones (FQs) have substantial activity against the Mycobacterium tuberculosis complex (MTBc) by preventing bacterial DNA synthesis through DNA gyrase inhibition. The reference standard for FQ-resistance testing is phenotypic drug-susceptibility testing (pDST) based on growth inhibition of MTBc in drug-containing Mycobacteria Growth Indicator Tube system (MGIT) media at a critical concentration (CC) that differentiates phenotypically wild-type from nonwild-type MTBc and at a clinical breakpoint that identifies strains that will likely still respond to treatment at higher doses. Despite the recent introduction of powerful new TB drugs, highly sensitive detection of clinically defined FQ resistance remains key.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method:<\/jats:title>\n                    <jats:p>In this study, we re-evaluated the current WHO-recommended CCs of Lfx (1.0 mg\/ml), Mfx (0.25 mg\/ml), Gfx (0.25 \u00b5g\/ml), and the nowadays, obsolete CC of Ofx (2.0 mg\/ml) for MGIT, using 147 MTBc isolates with known gyrA and gyrB sequences including both high-and low-level FQ resistance-conferring mutants. We tested a wide range of drug concentrations covering the current and former\/obsolete WHO-recommended CCs for FQs and some intermediate concentrations to challenge the current WHO-recommended CCs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The specificity of all four CCs was 100%. The sensitivities varied: 92.4% for Ofx and Lfx, 85.7% for Mfx, and 83.2% for Gfx. Lowering the CC of Mfx to 0.125 mg\/ml would allow to correctly classify all wild-type and mutant isolates while lowering the CC of Gfx to 0.125 mg\/ml would still misclassify some gyrA\/gyrB mutants as susceptible.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Based on our findings, a minimal inhibitory concentration of 0.125 mg\/ml on MGIT medium is a more appropriate CC for Mfx and probably also as a surrogate for overall FQ resistance in the MTBc.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijmy.ijmy_144_23","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T02:00:08Z","timestamp":1741140008000},"page":"316-323","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Re-evaluation of Critical Concentrations of Antituberculosis Fluoroquinolones in the Mycobacteria Growth Indicator Tube 960 System"],"prefix":"10.4103","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9858-8935","authenticated-orcid":false,"given":"Praharshinie","family":"Rupasinghe","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences, Unit of Mycobacteriology, Institute of Tropical Medicine, University of Antwerp, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Driesen","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases in Animals, Sciensano, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Vereecken","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Unit of Mycobacteriology, Institute of Tropical Medicine, University of Antwerp, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bouke C","family":"de Jong","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Unit of Mycobacteriology, Institute of Tropical Medicine, University of Antwerp, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leen","family":"Rigouts","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Unit of Mycobacteriology, Institute of Tropical Medicine, University of Antwerp, Antwerp, Belgium"},{"name":"Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,9,15]]},"reference":[{"key":"R1-20250306","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1093\/jac\/dkv360","article-title":"Specific gyrA gene mutations predict poor treatment outcome in MDR-TB","volume":"71","author":"Rigouts","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"R2-20250306","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/jac\/dkm061","article-title":"Fluoroquinolone resistance in Mycobacterium tuberculosis isolates:Associated genetic mutations and relationship to antimicrobial exposure","volume":"59","author":"Wang","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"R3-20250306","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1128\/AAC.42.8.2066","article-title":"In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis","volume":"42","author":"Ji","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"R4-20250306","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1128\/AAC.46.4.1022-1025.2002","article-title":"In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis","volume":"46","author":"Alvirez-Freites","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"R5-20250306","article-title":"Meeting Report of the WHO Expert Consultation on the Definition of Extensively Drug-Resistant Tuberculosis","year":"2021"},{"key":"R8-20250306","doi-asserted-by":"crossref","first-page":"M2","DOI":"10.1128\/microbiolspec.MGM2-0009-2013","article-title":"The molecular genetics of fluoroquinolone resistance in Mycobacterium tuberculosis","volume":"2","author":"Mayer","year":"2014","journal-title":"Microbiol Spectr"},{"key":"R9-20250306","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1093\/jac\/dkr566","article-title":"Asystematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system","volume":"67","author":"Maruri","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"R10-20250306","doi-asserted-by":"crossref","first-page":"e0120470","DOI":"10.1371\/journal.pone.0120470","article-title":"Frequency and geographic distribution of gyrA and gyrB mutations associated with fluoroquinolone resistance in clinical Mycobacterium tuberculosis isolates:A systematic review","volume":"10","author":"Avalos","year":"2015","journal-title":"PLoS One"},{"key":"R11-20250306","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1111\/j.1469-0691.2010.03087.x","article-title":"First report of molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates from a Tunisian hospital","volume":"16","author":"Soudani","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"R12-20250306","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1128\/JCM.05286-11","article-title":"High proportion of fluoroquinolone-resistant Mycobacterium tuberculosis isolates with novel gyrase polymorphisms and a gyrA region associated with fluoroquinolone susceptibility","volume":"50","author":"Devasia","year":"2012","journal-title":"J Clin Microbiol"},{"key":"R13-20250306","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1128\/AAC.01049-15","article-title":"Mutations in gyrA and gyrB among fluoroquinolone- and multidrug-resistant Mycobacterium tuberculosis isolates","volume":"60","author":"Chien","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"R14-20250306","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/ja.2014.95","article-title":"Prevalence of gyrA and B gene mutations in fluoroquinolone-resistant and -sensitive clinical isolates of Mycobacterium tuberculosis and their relationship with MIC of ofloxacin","volume":"68","author":"Singh","year":"2015","journal-title":"J Antibiot (Tokyo)"},{"key":"R15-20250306","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1128\/JCM.01947-09","article-title":"Detection by GenoType MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-resistant Mycobacterium tuberculosis complex isolates","volume":"48","author":"Brossier","year":"2010","journal-title":"J Clin Microbiol"},{"key":"R17-20250306","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1179\/1066981712Z.00000000025","article-title":"Challenges with diagnoses:Sketchy reference standards","volume":"20","author":"Cook","year":"2012","journal-title":"J Man Manip Ther"},{"key":"R21-20250306","first-page":"2274","article-title":"Determination of critical concentrations of moxifloxacin and gatifloxacin for drug susceptibility testing of Mycobacterium tuberculosis in the BACTEC MGIT 960 system","volume":"68","author":"Isaeva","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"R22-20250306","doi-asserted-by":"crossref","first-page":"7.e5","DOI":"10.1016\/j.cmi.2014.08.021","article-title":"Little difference between minimum inhibitory concentrations of Mycobacterium tuberculosis wild-type organisms determined with BACTEC MGIT 960 and Middlebrook 7H10","volume":"21","author":"Stureg\u00e5rd","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"R24-20250306","doi-asserted-by":"crossref","first-page":"e01550","DOI":"10.1128\/AAC.01550-17","article-title":"What is resistance?Impact of phenotypic versus molecular drug resistance testing on therapy for multi- and extensively drug-resistant tuberculosis","volume":"62","author":"Heyckendorf","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"R25-20250306","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.cmi.2019.01.019","article-title":"Standards for MIC testing that apply to the majority of bacterial pathogens should also be enforced for Mycobacterium tuberculosis complex","volume":"25","author":"Sch\u00f6n","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"R26-20250306","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.cmi.2022.02.024","article-title":"How to:ECOFFs-the why, the how, and the don'ts of EUCAST epidemiological cutoff values","volume":"28","author":"Kahlmeter","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"R27-20250306","doi-asserted-by":"crossref","first-page":"e672","DOI":"10.1016\/S2666-5247(22)00116-1","article-title":"Investigating resistance in clinical Mycobacterium tuberculosis complex isolates with genomic and phenotypic antimicrobial susceptibility testing:A multicentre observational study","volume":"3","author":"Finci","year":"2022","journal-title":"Lancet Microbe"},{"key":"R28-20250306","doi-asserted-by":"crossref","first-page":"e01663","DOI":"10.1128\/AAC.01663-20","article-title":"Molecular evaluation of fluoroquinolone resistance in serial Mycobacterium tuberculosis isolates from individuals diagnosed with multidrug-resistant tuberculosis","volume":"65","author":"Willby","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"R29-20250306","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1128\/AAC.01228-13","article-title":"Prevalence and molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates in China","volume":"58","author":"Zhang","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"R30-20250306","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.jmoldx.2020.06.010","article-title":"Specific gyrA gene mutations correlate with high prevalence of discordant levofloxacin resistance in Mycobacterium tuberculosis isolates from Beijing, China","volume":"22","author":"Huo","year":"2020","journal-title":"J Mol Diagn"},{"key":"R31-20250306","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ijantimicag.2012.02.015","article-title":"gyrA\/B fluoroquinolone resistance allele profiles amongst Mycobacterium tuberculosis isolates from mainland China","volume":"39","author":"Long","year":"2012","journal-title":"Int J Antimicrob Agents"}],"container-title":["The International Journal of Mycobacteriology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijmy.ijmy_144_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:55:08Z","timestamp":1787763308000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijmy.ijmy_144_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/ijmy.ijmy_144_23","relation":{},"ISSN":["2212-5531","2212-554X"],"issn-type":[{"value":"2212-5531","type":"print"},{"value":"2212-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"2023-05-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}